High-dose Chemotherapy as Second-line Drug Therapy for Relapsed Germ Cell Tumors - Trial NCT06418789
Access comprehensive clinical trial information for NCT06418789 through Pure Global AI's free database. This Phase 2 trial is sponsored by N.N. Petrov National Medical Research Center of Oncology and is currently Recruiting. The study focuses on Germ Cell Tumor. Target enrollment is 25 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
N.N. Petrov National Medical Research Center of Oncology
Timeline & Enrollment
Phase 2
Mar 01, 2024
Mar 01, 2029
Primary Outcome
Progression Free Survival (PFS)
Summary
This is a prospective, single-center, non-randomized phase II study. Patients with germ cell
 tumors of gonadal and extragonadal localization who have progressed after prior
 platinum-containing first-line chemotherapy will receive high-dose chemotherapy with TI (2
 cycles) folollowed by high dose CE chemotherapy with autologous stem cell transplantation (3
 cycles). The primary endpoint of the study is to evaluate the efficacy high-dose chemotherapy
 as second-line drug therapy for patients with advanced germ cell tumors.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06418789
Non-Device Trial